澳洲生物技术巨头CSL宣布分拆流感疫苗部门，并裁员15%
CSL(US:CSLLY) Ge Long Hui A P P·2025-08-19 00:45Group 1 - CSL plans to spin off its flu vaccine division, CSL Seqirus, into an independent publicly listed company by the end of fiscal year 2026 [1] - The company will implement a 15% workforce reduction as part of this restructuring [1] - CSL aims to resume its share buyback program, targeting AUD 750 million (approximately USD 486.98 million) in stock repurchases by the end of fiscal year 2026 [1]